Live Breaking News & Updates on Atara Biotherapeutics
Stay updated with breaking news from Atara biotherapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) has earned a consensus recommendation of “Hold” from the three research firms that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation. The average 12-month price objective among brokerages that have updated their coverage on the stock in […] ....
Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 11,030,000 shares, a growth of 8.8% from the February 29th total of 10,140,000 shares. Based on an average daily volume of 3,500,000 shares, […] ....
Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects. ....
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Free Report) have been given an average recommendation of “Hold” by the three research firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokers that have issued ratings on the […] ....